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A B S T R A C T
Cholesterol biosynthesis serves as a central metabolic hub for numerous biological processes in health
and disease. A detailed, integrative single-view description of how the cholesterol pathway is structured
and how it interacts with other pathway systems is lacking in the existing literature. Here we provide a
systematic review of the existing literature and present a detailed pathway diagram that describes the
cholesterol biosynthesis pathway (the mevalonate, the Kandutch-Russell and the Bloch pathway) and
shunt pathway that leads to 24(S),25-epoxycholesterol synthesis. The diagram has been produced using
the Systems Biology Graphical Notation (SBGN) and is available in the SBGN-ML format, a human
readable and machine semantically parsable open community ﬁle format.
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Cholesterol is an intensively studied, multi-functional lipid that
is key to many aspects of immunological, neuronal, viral and
hepatocyte biology. It is an essential component of cellular
membranes and is a precursor to steroids, bile acids and oxysterols
whilst its own precursors contribute to prenylation and dolichyla-
tion and the formation of vitamin D3. One of the oxysterols known
to be involved in linking sterol metabolism to innate immunity
[1,2] is 25-hydroxycholesterol. However its place in the sterol
metabolism has not yet been well established.
Despite the importance of the cholesterol synthesis pathway to
cellular function and its value in pharmaceutical therapies, an
integrative picture of how the pathway is structured has not been
well described in the literature, impeding the development of a
more rigorous understanding of the role of the cholesterol
metabolism in cellular processes. Publications typically focus on* Corresponding author at: Division of Pathway Medicine, University of
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Open access under CC BY license.segments of the cholesterol biosynthesis pathway showing
variable level of details. Kovacs and co-authors focus on the
mevalonate section of the pathway and on the subcellular location
of the enzymes involved [3]. Wang and co-authors concentrate on
the steps leading to 24(S),25-epoxycholesterol synthesis and their
similarity to steps in the cholesterol biosynthesis pathway [4].
Previous work studying the role of the cholesterol biosynthesis
pathway has shown a modest level of detail on the sterol arms of
the pathway [5–7] in innate immunity. The LIPID MAPS consor-
tium offers the most detailed descriptions of the Bloch and
Kandutsch-Russell branches of cholesterol biosynthesis, but these
lack cell compartment information and lack integration with the
24(S),25-epoxycholesterol shunt arm and other branching
pathways [8].
Here we present a comprehensive literature review of the
cholesterol synthesis pathway and we implement this as a detailed
pathway that captures enzymatic activity and compartmental
localization and summarizes all intermediate metabolic forms. Our
review also clearly indicates what information is missing and
where additional research is required.
2. Materials and methods
The model of the cholesterol biosynthesis pathway presented in
this work has been assembled using a variety of publicly available
resources including the research ﬁndings of the LipidMaps
A. Mazein et al. / Biochemical Pharmacology 86 (2013) 56–66 57consortium [8] and results obtained from thorough searches of the
published literature that have been manually curated and
validated by domain experts.
In cases where there were conﬂicting reports, preference was
given to the more recent papers and to the works in which more
reliable and advanced methods were used. The suggested order of
events is supported by a number of independently obtained
research results. The principles of the Evidence Ontology (ECO) [9],
the Gene Ontology Evidence Codes [10] and the Evidence Code
Decision Tree [11] were considered during the pathway recon-
struction.
A brief summary is provided for each enzyme and the
corresponding metabolic reactions involved in the pathway. For
each enzyme we endeavored to capture the following information
where available: corresponding gene name approved by HUGO
Gene Nomenclature Committee [12], alternative names, enzymo-
logical activities according to the Enzyme Nomenclature Commit-
tee of the IUBMB [13], enzyme function description, subunit
structure, subcellular location and related disorders.
We have included a list of UniProt IDs for the proteins captured
in the model (Table 1) and a list of metabolite names (common and
systematic) as used in the LipidMaps database [8] (Table 2).
Common names are used on the map where available.
The pathway that we present here is described using the
Systems Biology Graphical Notation (SBGN) [14], a community
driven consensus graphical schema for capturing the molecular
details of pathway systems. In particular, we use the SBGN Process
Description language [15]. A machine-readable model is available
as part of the supplementary material in SBGN-ML format [16] and
we present it graphically in Figs. 1–3, in an enhanced form. The
SBGN-ML format ﬁles can be read using a variety of software
packages.
In particular, the supplementary ﬁles provide a description
of the pathway that can be edited and modiﬁed in accordance
with the SBGN standard in order to be of future use to the
research community. The SBGN-ML ﬁle format encodes the
biological meaning associated with each component of the
model. This allows the model to be parsed by software (i) to
ensure that modiﬁcation is biologically valid and (ii) to
facilitate automatic generation of mathematical descriptions
of the pathway biology. It should be possible to open these ﬁles
in any software designed to comply with the SBGN-ML
standard, including but not limited to VANTED and Cytoscape
[17,18]. For the purpose of this review, we compiled and tested
the ﬁles using the VANTED software tool [17]. Here we shall
outline how the ﬁles can be opened and accessed using the
VANTED and CYTOSCAPE [18] software tools.
2.1. Accessing supplementary SBGN-ML ﬁles using the VANTED
software tool
2.1.1 Download the ﬁles with ‘.sbgn’ ﬁle extension from the
supplementary material.
2.1.2 Download and install VANTED from http://vanted.ipk-
gatersleben.de/.
2.1.3 Open VANTED and you will be greeted by a screen divided
into two regions: an empty area on the left for diagrams and a
column on the right containing settings under various tabs.
2.1.4 Using the automated installer to obtain the SBGN-ML add-
on.
2.1.4.1 In the right hand column select the ‘Help’ tab and then
the ‘Settings’ tab beneath and click on the ‘Install/Conﬁgure
Add-ons’ button. This will open the Add-on Manager.
2.1.4.2 Click on the ‘Find Add-ons/Updates’ button on the
bottom of the Add-on Manager window. This, in turn, opens the
‘Direct Add-on Download’ window.2.1.4.3 At the top right of the Add-ons window, left and right
arrows allow the user to move through a list of the available
Add-ons. Find the Add-on entitled, ‘SBGN-ED’ and click the
corresponding ‘Install Add-on’ button. VANTED will now
automatically download the SBGN extension.
2.1.4.4 Click ‘OK’ and you will return to the ‘Add-on Manager’
where ‘SBGN-ED’ will now be listed as an Add-on. Ensure that
the Active button is ticked beside the SBGN-ED entry to the list.
2.1.4.5 Click ‘OK’ on the ‘Add-on Manager’. The software is now
installed.
2.1.4.6 From the menus at on the top of the VANTED window,
select File>Open and choose your downloaded ﬁle with the
‘.sbgn’ ﬁle extension, in the usual way.
2.1.5 Manual installing the SBGN-ML add-on
2.1.5.1 From http://vanted.ipk-gatersleben.de/ Select Add-ons
and then ‘SBGN-ED – Editing, Translating and Validating of
SBGN Maps’.
2.1.5.2 Select ‘Download & Installation’ and then ‘SBGN-ED’
under downloads. A ﬁle called sbgn-ed.jar should start to
download.
2.1.5.3 Return to Vanted and in the right hand column select the
‘Help’ tab and then the ‘Settings’ tab beneath. Click on the
‘Install/Conﬁgure Add-ons’ button. This will open the Add-on
Manager.
2.1.5.4 Click the ‘Install Add-on’ button and select the sbgn-
ed.jar ﬁle downloaded previously. Click the ‘Install’ button. This
will return you to the ‘Add-on Manager’.
2.1.5.5 A message will appear the top of the Add-on Manager
window stating that ‘Add-on ‘‘sbgn-ed.jar’’ will be updated
when application is restarted’. Select OK and quit the program,
before relaunching it.
2.1.5.6 From the menus at on the top of the VANTED window,
select File>Open and choose your downloaded ﬁle with the
‘.sbgn’ ﬁle extension, in the usual way.
2.2. Accessing supplementary SBGN-ML ﬁles using the Cytoscape
software tool
2.2.1 Download and install Cytoscape from http://www.cytos-
cape.org/.
2.2.2 Open Cytoscape and select the Plugins menu followed by
‘Manage Plugins’.
2.2.3 In the search bar, type sbgn and hit return. Folders will
appear in the window and under ‘Available for install’ will
appear a Utility folder.
2.2.4 Open the utility folder and select the latest version of
CySBGN before hitting the install button. The CySBGN plugin
will then be downloaded and installed. Once it is installed, close
the ‘Manage Plugins’ window.
2.2.5 From the File menu select import followed by ‘Network
(Multiple File Types)’. In the window that opens, make sure that
the ‘Local’ option is chosen and high the ‘Select’ button to bring
up a ﬁle selector. Choose the downloaded ﬁle with the ‘sbgn’ ﬁle
extension in the usual way.
3. Results and discussion
3.1. Pathway maps
Fig. 1 shows the mevalonate arm of the cholesterol biosynthesis
pathway and includes enzymatic activity in the mitochondria,
peroxisome, cytoplasm and endoplasmic reticulum. The arm starts
with the consumption of acetyl-CoA, which occurs in parallel in
three cell compartments (the mitochondria, cytoplasm and
peroxisome) and terminates with the production of squalene in
Table 1
Uniprot IDs for the enzymes in the pathways shown in Figs. 1 and 2.
Uniprot ID Link EC Order Gene name Protein name Related disease Reference
P24752 http://www.uniprot.org/uniprot/P24752 2.3.1.9 1 ACAT1 Acetyl-CoA acetyltransferase, mitochondrial; THIL Alpha-methylacetoacetic
aciduria
OMIM #203750
Q9BWD1 http://www.uniprot.org/uniprot/Q9BWD1 2.3.1.9 1 ACAT2 Acetyl-CoA acetyltransferase, cytosolic ACAT2 deﬁciency OMIM #614055
Q01581 http://www.uniprot.org/uniprot/Q01581 2.3.3.10 2 HMGCS1 Hydroxymethylglutaryl-CoA synthase, cytoplasmic Not found OMIM #142940
P54868 http://www.uniprot.org/uniprot/P54868 2.3.3.10 2 HMGCS2 Hydroxymethylglutaryl-CoA synthase, mitochondrial HMG-CoA synthase deﬁciency OMIM #605911; PMID 16601895
P35914 http://www.uniprot.org/uniprot/P35914 4.1.3.4 3 HMGCL Hydroxymethylglutaryl-CoA lyase, mitochondrial HMG-CoA lyase deﬁciency OMIM #246450; PMID 17692550
P04035 http://www.uniprot.org/uniprot/P04035 1.1.1.34 4 HMGCR 3-Hydroxy-3-methylglutaryl-coenzyme A reductase Not found OMIM #142910
Q03426 http://www.uniprot.org/uniprot/Q03426 2.7.1.36 5 MVK Mevalonate kinase Mevalonic aciduria OMIM #610377; PMID 16722536
Q15126 http://www.uniprot.org/uniprot/Q15126 2.7.4.2 6 PMVK Phosphomevalonate kinase Not found OMIM #607622
P53602 http://www.uniprot.org/uniprot/P53602 4.1.1.33 7 MVD Mevalonate diphosphate decarboxylase Not found OMIM #603236
Q13907 http://www.uniprot.org/uniprot/Q13907 5.3.3.2 8 IDI1 Isopentenyl-diphosphate delta-isomerase 1 Not found OMIM #604055
Q9BXS1 http://www.uniprot.org/uniprot/Q9BXS1 5.3.3.2 8 IDI2 Isopentenyl-diphosphate delta-isomerase 2 Not found Not found
P14324 http://www.uniprot.org/uniprot/P14324 2.5.1.10;
2.5.1.1
9 FDPS Farnesyl diphosphate synthase;
dimethylallyltranstransferase
Not found Not found
O95749 http://www.uniprot.org/uniprot/O95749 2.5.1.29;
2.5.1.10;
2.5.1.1
10 GGPS1 Geranylgeranyl pyrophosphate synthase;
farnesyl diphosphate synthase;
dimethylallyltranstransferase
Not found Not found
P37268 http://www.uniprot.org/uniprot/P37268 2.5.1.21 11 FDFT1 Farnesyl-diphosphate farnesyltransferase 1;
squalene synthase
Not found OMIM #184420
Q14534 http://www.uniprot.org/uniprot/Q14534 1.14.13.132 12 SQLE Squalene monooxygenase; squalene epoxidase Not found OMIM #602019
P48449 http://www.uniprot.org/uniprot/P48449 5.4.99.7 13 LSS Lanosterol synthase Not found OMIM #600909
Q15392 http://www.uniprot.org/uniprot/Q15392 1.3.1.72 14 DHCR24 Delta(24)-sterol reductase;
24-dehydrocholesterol reductase
Desmosterolosis OMIM #602398; PMID 21559050
Q16850 http://www.uniprot.org/uniprot/Q16850 1.14.13.70 15 CYP51A1 Lanosterol 14-alpha demethylase;
cytochrome P450, family 51,
subfamily A, polypeptide 1
Not found OMIM #601637
O76062 http://www.uniprot.org/uniprot/O76062 1.3.1.70 16 TM7SF2 Delta(14)-sterol reductase;
transmembrane 7 superfamily member 2
Not found OMIM #603414
Q15800 http://www.uniprot.org/uniprot/Q15800 1.14.13.72 17 MSMO1;
SC4MOL
Methylsterol monooxygenase 1 Psoriasiform dermatitis;
microcephaly;
developmental delay
PMID 21285510
Q15738 http://www.uniprot.org/uniprot/Q15738 1.1.1.170 18 NSDHL Sterol-4-alpha-carboxylate 3-dehydrogenase,
decarboxylating; NAD(P) dependent steroid
dehydrogenase-like
CK syndrome; CHILD
syndrome
OMIM #300831; PMID 21129721;
OMIM #308050
P56937 http://www.uniprot.org/uniprot/P56937 1.1.1.270 19 HSD17B7 3-Keto-steroid reductase;
17-beta-hydroxysteroid dehydrogenase 7
Not found OMIM #606756
Q15125 http://www.uniprot.org/uniprot/Q15125 5.3.3.5 20 EBP 3-Beta-hydroxysteroid-delta(8),
Delta(7)-isomerase;
emopamil-binding protein
Conradi-Hu¨nermann-
Happle syndrome
OMIM #302960; PMID 21163155;
PMID 22229330
O75845 http://www.uniprot.org/uniprot/O75845 1.14.21.6 21 SC5DL Lathosterol oxidase; sterol-C5-desaturase
(ERG3 delta-5-desaturase homolog,
S. cerevisiae)-like
Lathosterolosis OMIM #607330; PMID 12189593
Q9UBM7 http://www.uniprot.org/uniprot/Q9UBM7 1.3.1.21 22 DHCR7 7-Dehydrocholesterol reductase Smith-Lemli-Opitz
syndrome (SLOS)
OMIM #270400; PMID 23059950;
PMID 23042628
P08684 http://www.uniprot.org/uniprot/P08684 1.14.13.97 23 CYP3A4 Cytochrome P450 3A4 Not found OMIM #124010
O95992 http://www.uniprot.org/uniprot/O95992 1.14.99.38 24 CH25H Cholesterol 25-hydroxylase Alzheimer’s disease OMIM #604551; PMID 20580938;
PMID 16909003
P22680 http://www.uniprot.org/uniprot/P22680 1.14.13.17 25 CYP7A1 Cholesterol 7-alpha-monooxygenase Not found OMIM #118455
Q02318 http://www.uniprot.org/uniprot/Q02318 1.14.13.15 26 CYP27A1 Sterol 26-hydroxylase, mitochondrial Cerebrotendinous
xanthomatosis
OMIM #606530; PMID 2019602;
PMID 8514861
Q9Y6A2 http://www.uniprot.org/uniprot/Q9Y6A2 1.14.13.98 27 CYP46A1 Cholesterol 24-hydroxylase Alzheimer’s disease OMIM #604087; PMID 12533085;
PMID 12533083
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Table 2
Systematics names, common names (where available) and LipidMaps IDs for the metabolites shown in Figs. 1 and 2.
Pathway LM_ID Common Name Systematic Name
Lanosterol biosynthesis LMFA07050029 Acetyl-CoA Acetyl-CoA
Lanosterol biosynthesis LMFA07050030 Acetoacetyl-CoA Acetoacetyl-CoA
Lanosterol biosynthesis LMFA07050028 HMG-CoA 3S-Hydroxy-3-methyl-glutaryl CoA
Lanosterol biosynthesis LMFA01050352 Mevalonic acid 3R-Methyl-3,5-dihydroxy-pentanoic acid
Lanosterol biosynthesis LMFA01050415 Mevalonate-P 3R-Methyl-3-hydroxypentanoic acid 5-phosphate
Lanosterol biosynthesis LMFA01050416 Mevalonate-PP 3R-Methyl-3-hydroxypentanoic acid 5-diphosphate
Lanosterol biosynthesis LMPR01010008 Isopentenyl-diphosphate 3-Methylbut-3-enyl pyrophosphate
Lanosterol biosynthesis LMPR01010001 Dimethylallyl-diphosphate 3-Methylbut-2-enyl pyrophosphate (dimethylallyl-diphosphate)
Lanosterol biosynthesis LMPR0102010001 Geranyl diphosphate Geranyl pyrophosphate
Lanosterol biosynthesis LMPR0103010002 Farnesyl diphosphate Farnesyl pyrophosphate
Lanosterol biosynthesis LMPR0106010003 Presqualene diphosphate Presqualene diphosphate
Lanosterol biosynthesis LMPR0106010002 Squalene Squalene
Lanosterol biosynthesis LMPR0106010010 3S-Squalene-2,3-epoxide 2,3S-Epoxy-2,6,10,15,19,23-hexamethyltetracosa-6E,10E,14E,18E,22-pentaene
Lanosterol biosynthesis LMST01010017 Lanosterol Lanosta-8,24-dien-3b-ol
Cholesterol biosynthesis (Bloch) LMST01010124 32-Hydroxylanosterol 4,4-Dimethyl-14a-hydroxymethyl-5a-cholesta-8,24-dien-3b-ol
Cholesterol biosynthesis (Bloch) LMST01010222 32-oxolanosterol 4,4-Dimethyl-14a-formyl-5a-cholesta-8,24-dien-3b-ol
Cholesterol biosynthesis (Bloch) LMST01010149 4,4-dimethylcholesta-8,11,24-trienol 4,4-Dimethyl-5a-cholesta-8,14,24-trien-3b-ol
Cholesterol biosynthesis (Bloch) LMST01010176 14-demethyllanosterol 4,4-Dimethyl-5a-cholesta-8,24-dien-3b-ol
Cholesterol biosynthesis (Bloch) LMST01010232 not available 4a-Hydroxymethyl-4b-methyl-5a-cholesta-8,24-dien-3b-ol
Cholesterol biosynthesis (Bloch) LMST01010229 not available 4a-Formyl-4b-methyl-5a-cholesta-8,24-dien-3b-ol
Cholesterol biosynthesis (Bloch) LMST01010150 4a-carboxy-4b-methyl-zymosterol 4a-Carboxy-4b-methyl-cholesta-8,24-dien-3b-ol
Cholesterol biosynthesis (Bloch) LMST01010237 3-Keto-4a-methyl-zymosterol 4a-Methyl-5a-cholesta-8,24-dien-3-one
Cholesterol biosynthesis (Bloch) LMST01010151 4a-Methyl-zymosterol 4a-Methyl-5a-cholesta-8,24-dien-3b-ol
Cholesterol biosynthesis (Bloch) LMST01010234 Not available 4a-Hydroxymethyl-5a-cholesta-8,24-dien-3b-ol
Cholesterol biosynthesis (Bloch) LMST01010226 Not available 4a-Formyl-5a-cholesta-8,24-dien-3b-ol
Cholesterol biosynthesis (Bloch) LMST01010152 4a-Carboxy-zymosterol 4a-Carboxy-5a-cholesta-8,24-dien-3b-ol
Cholesterol biosynthesis (Bloch) LMST01010168 Zymosterone 5a-Cholesta-8,24-dien-3-one
Cholesterol biosynthesis (Bloch) LMST01010066 Zymosterol 5a-Cholesta-8,24-dien-3b-ol
Cholesterol biosynthesis (Bloch) LMST01010206 5a-Cholesta-7,24-dien-3b-ol 5a-Cholesta-7,24-dien-3b-ol
Cholesterol biosynthesis (Bloch) LMST01010121 7-Dehydro-desmosterol Cholest-5,7,24-trien-3b-ol
Cholesterol biosynthesis (Bloch) LMST01010016 Desmosterol Cholest-5,24-dien-3b-ol
Cholesterol biosynthesis (Kandustch-Russell) LMST01010087 24,25-Dihydrolanosterol 5a-Lanost-8-en-3b-ol
Cholesterol biosynthesis (Kandustch-Russell) LMST01010224 Not available 4,4-Dimethyl-14a-hydroxymethyl-5a-cholest-8-en-3b-ol
Cholesterol biosynthesis (Kandustch-Russell) LMST01010223 Not available 4,4-Dimethyl-14a-formyl-5a-cholest-8-en-3b-ol
Cholesterol biosynthesis (Kandustch-Russell) LMST01010277 Not available 4,4-Dimethyl-5a-cholesta-8,14-dien-3b-ol
Cholesterol biosynthesis (Kandustch-Russell) LMST01010225 Not available 4,4-Dimethyl-5a-cholest-8-en-3b-ol
Cholesterol biosynthesis (Kandustch-Russell) LMST01010233 Not available 4a-Hydroxymethyl-4b-methyl-5a-cholest-8-en-3b-ol
Cholesterol biosynthesis (Kandustch-Russell) LMST01010230 Not available 4a-Formyl-4b-methyl-5a-cholest-8-en-3b-ol
Cholesterol biosynthesis (Kandustch-Russell) LMST01010227 Not available 4a-Carboxy-4b-methyl-5a-cholest-8-en-3b-ol
Cholesterol biosynthesis (Kandustch-Russell) LMST01010236 Not available 4a-Methyl-5a-cholest-8-en-3-one
Cholesterol biosynthesis (Kandustch-Russell) LMST01010197 4a-Methylcholest-8-en-3b-ol 4a-Methyl-5a-cholest-8-en-3b-ol
Cholesterol biosynthesis (Kandustch-Russell) LMST01010235 Not available 4a-Hydroxymethyl-5a-cholest-8-en-3b-ol
Cholesterol biosynthesis (Kandustch-Russell) LMST01010231 Not available 4a-Formyl-5a-cholest-8-en-3b-ol
Cholesterol biosynthesis (Kandustch-Russell) LMST01010228 Not available 4a-Carboxy-5a-cholest-8-en-3b-ol
Cholesterol biosynthesis (Kandustch-Russell) LMST01010239 Not available 5a-Cholest-8-en-3-one
Cholesterol biosynthesis (Kandustch-Russell) LMST01010096 Zymostenol 5a-Cholest-8-en-3b-ol
Cholesterol biosynthesis (Kandustch-Russell) LMST01010089 Lathosterol Cholest-7-en-3b-ol
Cholesterol biosynthesis (Kandustch-Russell) LMST01010069 7-Dehydrocholesterol Cholesta-5,7-dien-3b-ol
Cholesterol biosynthesis (Kandustch-Russell) LMST01010001 Cholesterol Cholest-5-en-3b-ol
Cholesterol biosynthesis (Kandustch-Russell/Bloch) LMST01010018 25-Hydroxy-cholesterol Cholest-5-en-3b,25-diol
Cholesterol biosynthesis (Kandustch-Russell/Bloch) LMST01010014 4b-Hydroxy-cholesterol Cholest-5-en-3b,4b-diol
Cholesterol biosynthesis (Kandustch-Russell/Bloch) LMST01010013 7a-Hydroxy-cholesterol Cholest-5-en-3b,7a-diol
Cholesterol biosynthesis (Kandustch-Russell/Bloch) LMST01010057 27-Hydroxy-cholesterol Cholest-5-en-3b,26-diol
Cholesterol biosynthesis (Kandustch-Russell/Bloch) LMST01010164 24-Hydroxy-cholesterol Cholest-5-en-3b,24-diol
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Fig. 1. The mevalonate arm of the cholesterol biosynthesis pathway presented in SBGN notation. An interactive, parsable version of this ﬁgure, encoded using the SBGN-ML
ﬁle format, is available in the supplementary material. The various glyph are explained in the legend in Fig. 3.
A. Mazein et al. / Biochemical Pharmacology 86 (2013) 56–6660the endoplasmic reticulum. Fig. 2 shows the sterol arms of the
cholesterol biosynthesis pathway and this includes the Bloch
pathway, the Kandutsch-Russell pathway and the shunt pathway.
This arm starts with Squalene and terminates with cholesterol
production on the Bloch and Kandutsch-Russell pathways and
with 24(S),25-epoxycholesterol on the shunt pathway. Fig. 3
provides a legend for the SBGN schema, explaining the various
nodes and edges.
3.2. Mevalonate arm of the cholesterol biosynthesis pathway
3.2.1. Acetyl-CoA acetyltransferase (ACAT1; ACAT2; Acetoa-
cetyl-CoA thiolase; EC 2.3.1.9) is an enzyme that catalyzes the
reversible condensation of two molecules of acetyl-CoA and forms
acetoacetyl-CoA. This reaction is an important step in ketone body
formation. Both mitochondrial ACAT1 and cytosolic ACAT2
enzymes are homotetramers [19,20]. Kovacs et al. suggest a
possibility of distribution of ACAT1 between peroxisomes and
mitochondria as experimental evidence supports the formation of
acetoacetyl-CoA in peroxisomes [3]. The proposed step in
peroxisomes is shown in Fig. 1 by a reaction glyph with a questionmark. Mutations of the ACAT1 gene cause alpha-methylacetoacetic
aciduria, an autosomal recessive disorder [21].
3.2.2. Hydroxymethylglutaryl-CoA synthase (HMGCS1;
HMGCS2; EC 2.3.3.10) forms HMG-CoA from acetyl-CoA and
acetoacetyl-CoA. The two proteins with this enzymological activity
are HMGCS1 and HMGCS2 (Table 1). HMGCS1 is a cytoplasmic
enzyme and HMGCS2 is localized to mitochondria and peroxisome
[3]. Ortiz and co-authors provide evidence for the involvement of
HMGCS2 in producing cholesterol-convertible HMG-CoA [22].
Peroxisomal localization of this enzyme was subsequently
conﬁrmed and the signiﬁcance of the peroxisomal pathway in
cholesterol production was demonstrated [39,40]. The schema
proposed by Kovacs and co-authors implies that the mitochondrial
component of HMG-CoA is being converted into acetyl-CoA and
acetoacetate by HMGCL (see 3.2.3) and is not likely to be involved
in further steps contributing to cholesterol formation [3]. The
possibility of HMG-CoA transport from the mitochondria to the
endoplasmic reticulum or peroxisome requires further study.
3.2.3. Hydroxymethylglutaryl-CoA lyase, mitochondrial
(HMGCL; EC 4.1.3.4) is a key enzyme in the ketone body formation
pathway that provides fuel to extrahepatic tissues [23]. It
Fig. 2. The sterol arms of the cholesterol biosynthesis pathway (shunt, Bloch and Kandutsch-Russell) presented in SBGN notation. An interactive, parsable version of this
ﬁgure, encoded using the SBGN-ML ﬁle format, is available in the supplementary material. The various glyph are explained in the legend in Fig. 3.
A. Mazein et al. / Biochemical Pharmacology 86 (2013) 56–66 61transforms HMG-CoA into acetyl-CoA and acetoacetate. HMGCL is
a mitochondrial enzyme and Kovacs et al. suggest peroxisomal
localization in addition to mitochondrial [3]. Since the peroxisomal
localization is not conﬁrmed yet, we show this step with a question
mark on the diagram (Fig. 1). The enzyme deﬁciency (HMGCLD) or
hydroxymethylglutaric aciduria may be due to a variety of
mutations and can be fatal [24].
3.2.4. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase
(HMGCR; EC 1.1.1.34) catalyzes the conversion of 3-hydroxy-3-
methylglutaryl-CoA into mevalonic acid. The enzyme is highly
regulated by relevant signaling pathways that include the SREBP
pathway [25]. Kovacs et al. conﬁrm endoplasmic reticulum
localization of HMGCR and provide evidence that suggestsperoxisomal localization [3]. In our model both locations for this
enzyme are included. This enzyme is conventionally regarded as
being rate limiting in the pathway and its interactions are targeted
by the statin class of drug.
3.2.5. Mevalonate kinase (MVK; ATP:mevalonate 5-phospho-
transferase; EC 2.7.1.36) catalyzes conversion of mevalonate into
phosphomevalonate. According to Hogenboom and co-authors
[26–29] mevalonate kinase (MVK), phosphomevalonate kinase
(PMK) and mevalonate pyrophosphate decarboxylase (MVD) are
cytosolic enzymes. This contradicts studies of Kovacs and co-
authors that conﬁrm their previous ﬁndings of peroxisomal
localization of the three enzymes [30] using stable isotopic
techniques and human cells [3]. MVK is regulated by intermediates
Fig. 3. The legend explaining the SBGN glyphs used in Figs. 2 and 3.
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competitively inhibited by farnesyl- and geranyl-pyrophosphates
[32]. Mutation of the MVK gene causes mevalonate kinase
deﬁciency [33], a disorder that leads to the lower activity of the
enzyme and the accumulation of mevalonic acid, resulting in
mevalonic aciduria [34] and hyperimmunoglobulinemia D syn-
drome [35].
3.2.6. Phosphomevalonate kinase (PMVK; EC 2.7.4.2) cata-
lyzes formation of mevalonate 5-diphosphate from mevalonate 5-
phosphate, an essential step in the mevalonate pathway. It is a
reversible reaction and kinetic constants have been determined for
human enzymes, both for forward and reverse reactions [36,37].
Expression of this enzyme is regulated in response to dietary sterol
levels and this regulation is coordinated with HMGCR [38].
Peroxisomal localization of the enzyme has been conﬁrmed
[3,30,38–40].
3.2.7. Diphosphomevalonate decarboxylase (MVD; meva-
lonate (diphospho) decarboxylase;  EC 4.1.1.33 is an enzyme
that decarboxylates mevalonate 5-diphosphate forming iso-
pentenyl diphosphate while hydrolyzing ATP. This enzyme is
considered to be a useful target for lowering serum cholesterol
levels [41] and is active as a homodimer [41]. Information onperoxisomal localization of diphosphomevalonate decarboxyl-
ase is provided in the section on mevalonate kinase (3.2.5).
3.2.8. Isopentenyl-diphosphate delta-isomerases (IDI1; IDI2;
EC 5.3.3.2) perform isomerization of isopentenyl diphosphate into
dimethylallyl diphosphate. These metabolites serve as fundamen-
tal building blocks of isoprenoids. This is an essential rate-limiting
regulatory step for isoprenoid biosynthesis [42]. There are two
types of isopentenyl-diphosphate delta-isomerase, IDI1 and IDI2.
They differ in their structure and activity [43]. Both enzymes act
via a proton addition/elimination mechanism [44]. IDI2 requires
the presence of a reduced ﬂavin mononucleotide cofactor [43] and
both enzymes are localized to the peroxisome [45].
3.2.9. Farnesyl diphosphate synthase (FDPS; EC 2.5.1.10; EC
2.5.1.1; Dimethylallyltranstransferase) catalyzes two reactions
that lead to farnesyl diphosphate formation. In the ﬁrst (EC 2.5.1.1
activity) isopentenyl diphosphate and dimethylallyl diphosphate
are transformed into geranyl diphosphate. Next, geranyl diphos-
phate and isopentenyl diphosphate are transformed into farnesyl
diphosphate (EC 2.5.1.10 activity). The enzyme is a homodimer
[46]. It is reported to be localized in peroxisomes [47]. FDPS
supplies precursors for synthesis of steroids, dolichols and
ubiquinones, protein fanesylation and geranylation. This enzyme
has been suggested as an important target for drug development
[48].
3.2.10. Geranylgeranyl pyrophosphate synthase (GGPS1; EC
2.5.1.29; EC 2.5.1.10; farnesyl diphosphate synthase; EC 2.5.1.1;
dimethylallyltranstransferase) is able to catalyze the two
reactions of farnesyl diphosphate formation. In addition, the
enzyme catalyzes the addition of three molecules of isopentenyl
diphosphate to dimethylallyl diphosphate and forms geranylger-
anyl diphosphate, an important precursor of geranylated proteins
[49] (EC 2.5.1.29 activity). The active enzyme is homohexamer [49]
and is assumed to be localized to the endoplasmic reticulum.
3.2.11. Farnesyl-diphosphate farnesyltransferase 1 (FDFT1;
EC 2.5.1.21; Squalene synthase) catalyzes a two-step reductive
dimerization of two farnesyl diphosphate molecules and synthe-
sizes squalene [50–52]. The FDFT1 expression level is regulated by
cholesterol status: the human FDFT1 gene has a complex promoter
with multiple binding sites for SREBP-1a and SREBP-2 [53].
3.3. Sterol arms of the sterol biosynthesis pathway
3.3.1. Squalene epoxidase (SQLE; EC 1.14.13.132; squalene
monooxygenase) catalyzes the conversion of squalene into
squalene-2,3-epoxide and the conversion of squalene-2,3-epoxide
(2,3-oxidosqualene) into 2,3:22,23-diepoxysqualene (2,3:22,23-
dioxidosqualene). The ﬁrst reaction is the ﬁrst oxygenation step in
the cholesterol biosynthesis pathway and the second reaction is
the ﬁrst step in 24(S),25-epoxycholesterol formation from
squalene-2,3-epoxide [4,54]. The steps are localized to the
endoplasmic reticulum membrane [55] and it has been suggested
that this is one of the rate-liming steps in the pathway [56].
3.3.2. Lanosterol synthase (LSS; OLC; OSC; 2,3-oxidosquale-
ne:lanosterol cyclase; EC 5.4.99.7) catalyzes cyclization of
squalene-2,3-epoxide to lanosterol and 2,3:22,23-diepoxysqua-
lene to 24(S),25-epoxylanosterol [4,54]. The active monomeric
enzyme is localized to the endoplasmic reticulum membrane [57].
Together with FDFT1 and SQLE, LSS has been considered as
prospective target for antihypercholesterolemia drugs as an
alternative to statin-based therapies [58,59].
3.3.3. Delta(24)-sterol reductase (DHCR24; 24-dehydro-
cholesterol reductase; EC 1.3.1.72) is a special enzyme in
cholesterol biosynthesis pathway due to its broad substrate
speciﬁcity. It catalyzes the reduction of the delta-24 double bond
of intermediate metabolites. In particular, DHCR24 converts
lanosterol into 24,25-dihydrolanostrol, the initial metabolite of
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of Bloch pathway converting desmosterol into cholesterol.
Intermediates of the Bloch pathway are converted by DHCR24
into intermediates of Kandutsch-Russell pathway [4]. Endoplas-
mic reticulum membrane localization has been conﬁrmed for the
enzyme [60]. Recent studies investigating the regulation of the
DHCR24 promoter present evidence of binding sites for SREBP-2
[61,62]. DHCR24 participates in the inﬂammatory response and
induces heme oxigenase-1, a potentially cardioprotective
enzyme [63]. Mutations in the DHCR24 gene causes desmoster-
olosis [64], a rare autosomal disorder that is characterized by
elevated level of desmosterol in tissues [65].
3.3.4. Lanosterol 14-alpha demethylase (CYP51A1; cyto-
chrome P450, family 51, subfamily A, polypeptide 1; EC
1.14.13.70) converts lanosterol into 4,4-dimethyl-5a-cholesta-
8,14,24-trien-3b-ol and 24,25-dihydrolanosterol into 4,4-dimeth-
yl-5a-cholesta-8,14-dien-3b-ol in three steps [8].
3.3.5. Delta(14)-sterol reductase (TM7SF2; transmembrane 7
superfamily member 2; EC 1.3.1.70) catalyzes reactions on the
three branches of the cholesterol and 24(S),25-epoxycholesterol
pathways [4,8]. This enzyme is localized to the endoplasmic
reticulum membrane [66].
3.3.6. Methylsterol monooxygenase 1 (MSMO1; SC4MOL; C-4
methylsterol oxidase; EC 1.14.13.72) catalyzes demethylation of
C4-methylsterols [8]. This protein is localized to the endoplasmic
reticulum membrane [67]. Mutations in the MSMO1 gene cause
psoriasiform dermatitis, microcephaly and developmental delay
[68].
3.3.7. Sterol-4-alpha-carboxylate 3-dehydrogenase, decar-
boxylating (NSDHL; NAD(P) dependent steroid dehydrogenase-
like; EC 1.1.1.170) participates in several steps of post-squalene
cholesterol and 24(S),25-epoxycholesterol synthesis [4,8]. Defects
in the NSDHL gene cause CK syndrome [69], recessive mental
retardation syndrome [70] and CHILD syndrome [71], congenital
hemidysplasia with ichythyosiform erythrodema and limb defects
[72].
3.3.8. 3-keto-steroid reductase (HSD17B7; 17-beta-hydro-
xysteroid dehydrogenase 7; EC 1.1.1.270) was the last unknown
enzyme of mammalian cholesterol biosynthesis [73]. It was
previously reported in the regulation of the activity of sex steroids
[4,8,73,74]. It converts zymosterone into zymosterol in the Bloch
pathway.
3.3.9. 3-Beta-hydroxysteroid-delta(8),delta(7)-isomerase
(EBP; emopamil-binding protein; EC 5.3.3.5) catalyzes the
conversion of delta(8)-sterols into delta(7)-sterols. Mutations in
the EBP gene cause Conradi-Hunermann-Happle syndrome [75]
characterized by punctiform calciﬁcation in the bones [76,77]. It is
an endoplasmic reticulum membrane localized protein [78].
3.3.10. Lathosterol oxidase (SC5DL; Sterol-C5-desaturase
(ERG3 delta-5-desaturase homolog, S. cerevisiae)-like; EC
1.14.21.6) catalyzes the production of 7-dehydrocholesterol, 7-
dehydrodesmosterol and 24(S),25-epoxy-7-dehydrocholesterol
[5]. Endoplasmic reticulum membrane localization has been
suggested [79]. Lanosterol side chain amines were reported to
be selective inhibitors for lathosterol oxidase [80] and together
with other inhibitors for the post-squalene enzymes of the
cholesterol biosynthesis pathway were suggested as potential
targets for therapies to reduce the risk of cardiovascular disease
[81]. Defects in the enzyme are the cause of lathosterolosis [82], an
autosomal recessive disorder that is characterized by multiple
congenital anomalies and liver disease [83].
3.3.11. 7-Dehydrocholesterol reductase (DHCR7; EC 1.3.1.21)
catalyses reduction of the C7–C8 double bond of 7-dehydrocho-
lesterol and formation of cholesterol. It also produces desmosterol
from 7-dehydrodesmosterol [8] and 24(S),25-epoxycholesterol
from 24(S),25-epoxy-7-dehydrocholesterol [4]. Mutations in thegene that encodes DHCR7 causes Smith-Lemli-Opitz syndrome, a
recessively inherited autosomal disease [84].
3.3.12. Cytochrome P450, family 3, subfamily A, polypeptide
4 (CYP3A4; 1,8-cineole 2-exo-monooxygenase; taurocheno-
deoxycholate 6a-hydroxylase; EC 1.14.13.97) catalyses the
hydroxylation of cholesterol leading to 25-hydroxycholesterol
[85] and 4b-hydroxycholesterol [86,87]. It is localized to the
endoplasmic reticulum [88].
3.3.13. Cholesterol 25-hydroxylase (CH25H; Cholesterol 25-
monooxygenase; EC 1.14.99.38) uses di-iron cofactors to catalyze
the hydroxylation of cholesterol [89–91] to produce 25-hydro-
xycholesterol. Has the capacity to catalyze the transition of 24-
hydroxycholesterol to 24,25-dihydroxycholesterol. It is an endo-
plasmic reticulum localized enzyme [89] and has been shown to
have a role in innate immunity [1,2]. Mutations have been
associated with Alzheimer’s disease [92,93].
3.3.14. Cytochrome P450, family 7, subfamily A, polypeptide
1 (CYP7A1; cholesterol 7-alpha-hydroxylase; EC 1.14.13.17)
responsible for introducing a hydrophilic moiety at position 7 of
cholesterol to form 7a-hydroxycholesterol [94]. It is localized to
the endoplasmic reticulum [95].
3.3.15. Cytochrome P450, family 27, subfamily A, polypeptide
1 (CYP27A1; Sterol 27-hydroxylase; EC 1.14.13.15) was the ﬁrst
hydroxylase to be isolated [96]. It catalyses the transition of
mitochondrial cholesterol to 27-hydroxycholesterol [97] and 25-
hydroxycholesterol [98,99]. It is localized to the mitochondria [97]
and mutations are associated with the recessive autosome disorder
Cerebrotendinous Xanthomatosis [100].
3.3.16. Cytochrome P450 46A1 (CYP46A1, cholesterol 24-
hydroxylase, EC 1.14.13.98) catalyses transformation of choles-
terol into 24(S)-hydroxycholesterol. Localized to endoplasmic
reticulum membrane [101], the enzyme is mainly expressed in
brain tissue and is considered to be an important biomarker for
neurodegenerative disorders [102–105].
3.4. Oxysterol 24(S),25-epoxycholesterol synthesis from squalene
24(S),25-Epoxycholesterol is produced in a shunt pathway that
is parallel to the two branches of the cholesterol synthesis pathway
[4,106–108]. The same set of enzymes is involved in the formation
of cholesterol from 24,25-dihydrolanosterol in the Kandutsch-
Russell pathway, desmosterol from lanosterol in the Bloch
pathway and 24(S),25-epoxycholesterol from 24(S),25-epoxyla-
nosterol in a shunt pathway [4]. Due to its importance in
regulatory processes 24(S),25-epoxycholesterol is in the focus of
several recent publications [107,109–112]. However, further
research is necessary to conﬁrm each step of the shunt pathway
and the corresponding intermediate metabolites. In our represen-
tation, the known intermediates of the shunt pathway are shown
and likely missing information is noted with the appropriate SBGN
glyph.
3.5. Transport of the intermediate metabolites between different
cellular compartments
Little is known about transporting of the intermediate
metabolites of the cholesterol biosynthesis pathway between
different cellular compartments. It is not known whether
metabolites in the mitochondria participate in cholesterol
biosynthesis and, in a number of cases, it is unclear whether
metabolites move between compartments through diffusion
or transportation. This is something that should be addressed
in the future. It has been suggested that limitations in
subcellular fractionation methods are a signiﬁcant factor in
our poor understanding of the subcellular localization of these
enzymes [3].
A. Mazein et al. / Biochemical Pharmacology 86 (2013) 56–66644. Concluding remarks
The diagrams presented here show a comprehensive view of
the mevalonate, Kandutsch-Russell, Bloch and shunt pathways.
The diagrams are described using the SBGN schema, an open and
community developed graphical language for unambiguously
capturing pathway structure. Missing/uncertain information is
clearly marked on the pathway diagrams and shows the areas that
need to be further explored. Models of these diagrams are
available as supplementary material in the SBGN-ML and SBML/
CellDesigner [113] ﬁle formats for future development and
reﬁnement.
We hope that by elucidating and integrating the detailed
structure of this pathway, we will contribute to a ﬁner level of
understanding of cholesterol metabolism and its function and that
this will serve as a useful resource for future studies of the
cholesterol biosynthesis pathway.
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